SEARCH

SEARCH BY CITATION

References

  • 1
    Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders In: JaffeES, HarrisNL, SteinH, VardimanJW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 264 pp.
  • 2
    Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29.
  • 3
    Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375.
  • 4
    Trofe J, Buell JF, Beebe TM, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5: 775.
  • 5
    Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076.
  • 6
    Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8: 139.
  • 7
    Herzig KA, Juffs HG, Norris D, et al. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int 2003; 16: 529.
  • 8
    Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998; 22: 299.
  • 9
    Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005; 23: 7574.
  • 10
    Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.
  • 11
    Pasquale MA, Weppler D, Smith J, et al. Burkitt's lymphoma variant of post-transplant lymphoproliferative disease (PTLD). Pathol Oncol Res 2002; 8: 105.
  • 12
    Sekiguchi N, Nishimoto J, Tanosaki R, et al. EBV-positive Burkitt lymphoma as a late-onset posttransplantation lymphoproliferative disorder after allogeneic stem cell transplantation. Int J Hematol 2004; 79: 387.
  • 13
    Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66: 1770.
  • 14
    Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 956.
  • 15
    Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622.
  • 16
    Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333.
  • 17
    Komrokji RS, Oliva JL, Zand M, Felgar R, Abboud CN. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol 2005; 79: 211.
  • 18
    Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9: 3945S.
  • 19
    Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 2004; 8: 87.
  • 20
    Elstrom RL, Andreadis C, Aqui NA, Tsai DE. Treatment of post-transplant lymphoproliferative disorder (PTLD) with rituximab or chemotherapy: the University of Pennsylvania experience. Blood 2005; 106: Abstract No: 936.
  • 21
    Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23: 6481.
  • 22
    Trappe R, Oertel S, Choquet S, LeBlond V, Papp-Vary M, Riess H. Sequential treatment with the anti-CD 20 antibody rituximab and CHOP + GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): first interim analysis of a multicenter phase II study. Blood 2005; 106: Abstract No: 932.
  • 23
    Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234.
  • 24
    Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 2001; 13: 360.
  • 25
    McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.
  • 26
    Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848.
  • 27
    Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335: 721.
  • 28
    Mentzer SJ, Perrine SP, Faller DV. Epstein–Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 2001; 3: 177.
  • 29
    Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5: 1415.
  • 30
    Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807.
  • 31
    Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451.
  • 32
    Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137.
  • 33
    Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435.
  • 34
    Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450.
  • 35
    Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644.
  • 36
    Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177.
  • 37
    Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581.
  • 38
    Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443.
  • 39
    Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109.
  • 40
    Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754.
  • 41
    Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940.
  • 42
    Weng WK, Stavenhagen J, Koenig S, Levy R. Rituximab variants with re-engineered Fc with higher affinity to activating FcγR eliminate the functional difference between FcγR genotypes. Blood 2005; 106: Abstract No: 347.
  • 43
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825.
  • 44
    Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 1103.
  • 45
    Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851.
  • 46
    Chong EA, Svoboda J, Cherian S, et al. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk Lymphoma 2005; 46: 1383.
  • 47
    Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088.
  • 48
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117.
  • 49
    Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572.
  • 50
    Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005; 64: 1087.
  • 51
    Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580.
  • 52
    Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062.
  • 53
    Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003; 143: 674.
  • 54
    Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511.
  • 55
    Ramanathan S, Koutts J, Hertzberg MS. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol 2005; 78: 123.
  • 56
    Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79: 504.
  • 57
    Usuda M, Fujimori K, Koyamada N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005; 79: 12.
  • 58
    Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 2005; 19: 137.
  • 59
    Aranda Jr JM, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002; 73: 907.
  • 60
    Kimby E. Tolerability and safety of rituximab (MabThera((R))). Cancer Treat Rev 2005; 31: 456.
  • 61
    Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655.
  • 62
    Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68.
  • 63
    Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85: 894.
  • 64
    Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96: 1184.
  • 65
    Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
  • 66
    Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998; 352: 1285.
  • 67
    Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112.
  • 68
    Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003; 17: 417.
  • 69
    Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005; 5: 566.
  • 70
    Serinet MO, Jacquemin E, Habes D, Debray D, Fabre M, Bernard O. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 2002; 34: 389.
  • 71
    Dotti G, Rambaldi A, Fiocchi R, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001; 86: 618.
  • 72
    Zompi S, Tulliez M, Conti F, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol 2000; 32: 521.
  • 73
    Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003; 16: 202.
  • 74
    Bueno J, Ramil C, Somoza I, et al. Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child. Pediatr Transplant 2003; 7: 153.
  • 75
    Herman J, Vandenberghe P, van den Heuvel I, Van Cleemput J, Winnepenninckx V, Van Damme-Lombaerts R. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. J Heart Lung Transplant 2002; 21: 1304.
  • 76
    Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001; 20: 770.
  • 77
    Al-Akash SI, Al Makadma AS, Al Omari MG. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant 2005; 9: 249.
  • 78
    Abderrahim E, Karoui C, Smaoui W, et al. Anti-CD20 antibodies to treat lymphoproliferative syndromes following renal transplantation. Transplant Proc 2003; 35: 2708.
  • 79
    Jenkins D, DiFrancesco L, Chaudhry A, et al. Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplant 2002; 30: 321.
  • 80
    Skoda-Smith S, Douglas VK, Mehta P, Graham-Pole J, Wingard JR. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab. Bone Marrow Transplant 2001; 27: 329.
  • 81
    Stachel DK, Schmid I, Schuster F, Stehr M, Baumeister FA, Muller-Hocker J. Lymphoproliferative syndrome in an infant after stem cell transplantation: successful therapy with T-lymphocytes and anti-CD20 monoclonal antibodies. Med Pediatr Oncol 2000; 35: 503.
  • 82
    Hanel M, Fiedler F, Thorns C. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 2001; 24: 491.
  • 83
    Yedibela S, Reck T, Niedobitek G, et al. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Transpl Int 2003; 16: 197.
  • 84
    Garcia VD, Bonamigo-Filho JS, Neumann J, et al. Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases. Transplant Proc 2002; 34: 2993.
  • 85
    Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73: 100.
  • 86
    Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502.
  • 87
    Berney T, Delis S, Kato T, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation 2002; 74: 1000.
  • 88
    Webber S, Harmon W, Faro A, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: multicenter experience from a registry and from a prospective clinical trial. Blood 2004; 104: Abstract No: 746.
  • 89
    Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 67.
  • 90
    Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124: 1242.
  • 91
    Ghobrial IM, Habermann TM, Ristow K, Ansell SM, McGregor CG, ONeill BP. Post-transplant lymphoproliferative disorders involving the central nervous system (CNS-PTLD): therapy with rituximab. Blood 2003; 102: Abstract No: 4913.
  • 92
    Ferry CK, Maillard A, Agbalika F, et al. Treatment of B-lymphoproliferative disorder after hematopoietic stem cell transplantation. Role and immunological follow-up of Rituximab®. Blood 2002; 100: Abstract No: 420.
  • 93
    Gonzalez-Barca E, Domingo-Domenech E, Gomez-Codina J, et al. First-line treatment with rituximab improves survival of patients with post-transplant lymphoproliferative disease (PTLD). Blood 2004; 104: Abstract No: 1406.
  • 94
    Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl. 1): 113.
  • 95
    Morrison VA, Bartlett N, Dunn DL, Peterson BA. Rituximab therapy for post-transplant lymphoproliferative disorders (PTLD): preliminary outcome results. Proc of ASCO Ann Meet 2001; Abstract No: 1177.
  • 96
    Horwitz SM, Tsai DE, Twist C, et al. Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: a prospective trial in adults and children. Proc of ASCO Ann Meet 2001; Abstract No: 1134.
  • 97
    Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901.
  • 98
    Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2005 [prepublished online 27 October 2005].
  • 99
    van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364.
  • 100
    Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77: 76.
  • 101
    Polito L, Bolognesi A, Tazzari PL, et al. The conjugate rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia 2004; 18: 1215.
  • 102
    Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725.
  • 103
    Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46: 191.